This PubMed entry documents a retraction notice for the study titled "Novel pharmacological inhibition of EZH2 attenuates septic shock by altering innate inflammatory responses to sepsis." The retraction notice was published in Int Immunopharmacol and is indexed with PubMed ID 42642306 and DOI 10.1016/j.intimp.2026.117301. The record shows the notice as published online ahead of print on 2026 Aug 26.
The retraction notice lists the full author group for the original work: Qianqian Zhang, Hong Sun, Shougang Zhuang, Na Liu, Xiaowei Bao, Xiandong Liu, Huijuan Ren, Diyu Lv, Zhe Li, Jianwen Bai, Xiaohui Zhou, and Lunxian Tang.
Author affiliations reported in the PubMed entry include:
The PubMed record also includes electronic contact addresses for two authors as listed in the affiliation block: Xiaohui Zhou (xhzhou100@126.com) and Lunxian Tang (lunxiantang@hotmail.com).
The entry is cataloged on PubMed as a published erratum/retraction notice in Int Immunopharmacol. It carries the DOI 10.1016/j.intimp.2026.117301 and the date line indicating online availability on 2026 Aug 26 with an internal article identifier (117301). No abstract content is provided within the PubMed record.
PubMed links this retraction notice directly to the original 2019 article: Zhang Q, Sun H, Zhuang S, et al. Int Immunopharmacol. 2019 Nov;76:105899. That original article was indexed under PMID 31518916 and DOI 10.1016/j.intimp.2019.105899. The PubMed entry explicitly identifies the 2019 citation in the "Erratum for" section, indicating that the 2019 study on pharmacologic inhibition of EZH2 in septic shock is the subject of the retraction notice.
The PubMed record for the retraction notice contains no abstract and provides no explanatory text detailing the reason(s) for the retraction. The entry is labeled under Publication types as a "Published Erratum." The database entry therefore does not report investigation findings, author statements, journal editorial notes, or corrective data. If additional explanation exists, it is not included in the PubMed record and would need to be sought from the journal publisher (Int Immunopharmacol) or the full text of the retraction notice on the publisher's platform.
The presence of a retraction notice linked to the 2019 publication indicates that clinicians and researchers should not treat the findings of the original paper as reliable without consulting the retraction text or publisher statement.
Because PubMed does not include the retraction rationale in this record, readers who have previously cited or relied on the 2019 study should contact the journal or consult the publisher’s website for the full retraction notice and any editorial explanation.
Bibliographic records and systematic reviews that included the 2019 study should be updated to reflect the retraction. Where possible, replace or annotate references with the retraction notice citation (PMID 42642306, DOI 10.1016/j.intimp.2026.117301).
Use the PubMed metadata when citing the retraction notice in bibliographies: the PubMed entry gives PMID 42642306 and DOI 10.1016/j.intimp.2026.117301. The record includes a direct link to the original 2019 article (PMID 31518916) in the "Erratum for" section.
Because the PubMed entry does not include an abstract or explanatory content, users seeking the full text of the retraction notice should access Int Immunopharmacol via the DOI link or the journal platform to retrieve the publisher’s notice and any editorial statement.
Note: This rewritten summary is limited to the information present in the PubMed record. The PubMed entry does not report specific reasons, investigation details, or author statements concerning the retraction; those details were not provided in the source record and must be obtained from the journal publisher if required.